A recent assessment of characteristics of the clinical trials recorded in the US-based registry ClinicalTrials.gov raises questions about the best methods for generating evidence as well as the capacity of clinical trials to supply sufficient amounts of high quality evidence needed to ensure confidence in guideline recommendations. Now armed with this increased level of data from the registry, the study’s authors conclude that the desire to provide high quality evidence for medical decisions must include consideration of a comprehensive redesign of the clinical trials enterprise. That these issues hold for interventional trials suggests that other strands of clinical research, notably those focused on comparative effectiveness, face similar if not even greater challenges to be able to provide meaningful real-world evidence.
Issues Abound Tracking Efficacy And Effectiveness In Clinical Trials
A recent JAMA paper assesses the progress of ClinicalTrials.gov, concluding that concerns continue around the use of best methods for generating evidence and the capacity of the clinical trials enterprise to supply the high quality evidence needed to ensure confidence in guidelines. That these issues hold for interventional trials suggests that other strands of clinical research, notably those focused on comparative effectiveness, face similar if not even greater challenges to be able to provide meaningful real-world evidence.
More from Clinical Trials
More from R&D
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.